Pilot Trial of a Game Embedded in a Smartphone App for Smoking Cessation

December 14, 2023 updated by: University of California, San Francisco

Influence of a Game Embedded in a Smartphone App for Smoking Cessation on User Engagement: A Randomized Pilot Trial

This study evaluates the effects of a video game embedded in a commercially available mobile application (app) for smoking cessation. Smokers are increasingly turning to mobile health apps for assistance with quitting smoking, and there is a critical need for strategies to engage app users to increase retention and efficacy. Video games are designed to increase users' motivation and engagement, which in turn may increase their exposure and adherence to a smoking cessation program. The hypothesis is that the game increases engagement, retention, and smoking abstinence rates compared with a core version of the app without the game. A two-arm individually randomized pilot trial of 500 adult smokers will test this hypothesis, comparing outcomes for participants randomized to receive the core app plus embedded game with participants randomized to receive the core app only. Primary outcomes relate to user engagement with the app. Secondary outcomes relate to user engagement, efficacy (smoking abstinence), and user satisfaction.

Study Overview

Detailed Description

PRIMARY OBJECTIVES:

I. Augment an existing smartphone cessation app for smoking cessation with a video game to increase user engagement.

II. Test the feasibility, engagement, and early efficacy of the 'gamified' app, compared to one without gamification.

OUTLINE:

Participants are recruited through the Smoke Free smartphone app and randomized to 1 of 2 arms.

ARM I: Participants receive an educational intervention through the Smoke Free application (core app) with the embedded video game module. Participants complete questionnaires and may undergo saliva sample collection, if they report being smoke-free on follow-up.

ARM II: Participants receive an educational intervention through the Smoke Free application without the video game module (core app only). Participants complete questionnaires and may undergo saliva sample collection, if they report being smoke-free on follow-up.

Study Type

Interventional

Enrollment (Actual)

500

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • San Francisco, California, United States, 94143
        • University of California San Francisco

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion criteria:

  1. Provides electronic informed consent.
  2. Male or female, aged 18 and older
  3. Has downloaded and opened the Smoke Free app
  4. A smoker of at least 1 cigarette per day
  5. Plans to quit smoking within the next 7 days
  6. Speaks, reads, and writes English
  7. Lives in the United States

Exclusion criteria: None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Education plus game module
Participants receive an educational intervention through the Smoke Free application with the embedded game module. Participants complete questionnaires and may undergo saliva sample collection, if they report being smoke-free on follow-up.
Receive access to the the game module through the free, 'Smoke Free' smartphone application
Other Names:
  • In-application game module
Receive educational intervention through the free 'Smoke Free' smartphone application (core version of the app)
Other Names:
  • Educational intervention
Active Comparator: Education module only
Participants receive an educational intervention through the Smoke Free application only (core app only). Participants complete questionnaires and may undergo saliva sample collection, if they report being smoke-free on follow-up.
Receive educational intervention through the free 'Smoke Free' smartphone application (core version of the app)
Other Names:
  • Educational intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Unique App Sessions
Time Frame: Enrollment through 56 days after participant's selected quit date (56 to 63 days total)
Number of times the app was opened; passively collected by the app and averaged in analysis to calculate mean number of app opens by study group over the study period. A new session is defined as use of the app after at least 30 minutes of inactivity.
Enrollment through 56 days after participant's selected quit date (56 to 63 days total)
Minutes of App Usage Per Session
Time Frame: Enrollment through 56 days after participant's selected quit date (56 to 63 days total)
Passively collected by the app and averaged in analysis among those with a session to calculate mean number of minutes of usage per session by study group.
Enrollment through 56 days after participant's selected quit date (56 to 63 days total)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Unique Days With at Least One App Session
Time Frame: Enrollment through 56 days after participant's selected quit date (56 to 63 days total)
Number of unique days with at least one app session, passively collected by the app and averaged by study group.
Enrollment through 56 days after participant's selected quit date (56 to 63 days total)
Self-reported 7-day Point-prevalence Abstinence at 2 Months
Time Frame: 56 days after participant's selected quit date (56 to 63 days after enrollment)
Proportion of participants who self-report having abstained for the prior 7 days during the 2-month follow-up assessment, assuming missing = smoking.
56 days after participant's selected quit date (56 to 63 days after enrollment)
Self-reported 30-day Point-prevalence Abstinence at 2 Months
Time Frame: 56 days after participant's selected quit date (56 to 63 days after enrollment)
Proportion of participants who who self-report having abstained for the prior 30 days during the 2-month follow-up assessment, assuming missing = smoking.
56 days after participant's selected quit date (56 to 63 days after enrollment)
Satisfaction With App
Time Frame: 56 days after participant's selected quit date (56 to 63 days after enrollment)
Rating of satisfaction with assigned app on a 5-point Likert scale from "Not at all" (1) to "Extremely" (5), assessed in the 2-month follow-up questionnaire. The measure is averaged by study group.
56 days after participant's selected quit date (56 to 63 days after enrollment)
Satisfaction With Game (Intervention Group Only)
Time Frame: 56 days after participant's selected quit date (56 to 63 days after enrollment)
Rating of satisfaction with the game on a 5-point Likert scale from "Not at all" (1) to "Extremely" (5), assessed in the 2-month follow-up questionnaire. The measure is averaged for the intervention group.
56 days after participant's selected quit date (56 to 63 days after enrollment)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Biochemically Verified 7-day Point-prevalence Abstinence at 2 Months
Time Frame: 56 days after participant's selected quit date (56 to 63 days after enrollment)
Proportion of participants who who self-report having abstained for the prior 7 days during the 2-month follow-up assessment, verified by saliva cotinine test, assuming missing = smoking. Averaged by study group. Recoded to 0 if the person reported having smoked during the same 7-day window during repeated measurement of daily smoking in the app.
56 days after participant's selected quit date (56 to 63 days after enrollment)
Biochemically Verified 30-day Point-prevalence Abstinence at 2 Months
Time Frame: 56 days after participant's selected quit date (56 to 63 days after enrollment)
Proportion of participants who who self-report having abstained for the prior 30 days during the 2-month follow-up assessment, verified by saliva cotinine test, assuming missing = smoking. Averaged by study group. Recoded to 0 if the person reported having smoked during the same 30-day window during repeated measurement of daily smoking in the app.
56 days after participant's selected quit date (56 to 63 days after enrollment)
Repeated 1-day Point-prevalence Smoking Abstinence
Time Frame: During the 56 days after participant's selected quit date
Proportion of days in which participants self-report having abstained in the last 24 hours, collected via a pop-up box that appears the first time each day a participant opens the app. Averaged by study group.
During the 56 days after participant's selected quit date
Program Adherence (Index of Core Feature Use)
Time Frame: Enrollment through 56 days after participant's selected quit date (56 to 63 days total)
Number of non-game (core app) activities completed in the app by activity type: passively collected by the app to assess number of times the participant completed the following activity types: reported a craving, recorded a diary, completed a mission, read a tip, used the chatbot.
Enrollment through 56 days after participant's selected quit date (56 to 63 days total)
Gifts Unlocked (Intervention Group Only)
Time Frame: Enrollment through 56 days after participant's selected quit date (56 to 63 days total)
Number of in-game gifts unlocked during the study period (intervention group only); a summary measure of intensity of engagement (dose of treatment) of the app; passively collected by the app.
Enrollment through 56 days after participant's selected quit date (56 to 63 days total)
Game Activities (Intervention Group Only)
Time Frame: Enrollment through 56 days after participant's selected quit date (56 to 63 days total)
Number of game activities completed in the app by activity type; passively collected by the app to assess number of times the participant completed the following activity types: navigated to the game dashboard, completed each pet care activity (breathing exercise, feeding, washing, memory mini-game), visited the park, entered the dragon guide.
Enrollment through 56 days after participant's selected quit date (56 to 63 days total)
Recommends App to Friend
Time Frame: 56 days after participant's selected quit date (56 to 63 days after enrollment)
Rating of whether would recommend assigned app to a friend on a 5-point Likert scale from "Not at all" (1) to "Extremely" (5), assessed in the 2-month follow-up questionnaire. The measure is averaged by study group.
56 days after participant's selected quit date (56 to 63 days after enrollment)
Motivation to Quit
Time Frame: 56 days after participant's selected quit date (56 to 63 days after enrollment)
Motivation to quit, reported on a 10-point scale from not at all motivated (0) to very unmotivated (10) and assessed in the 2-month follow-up.
56 days after participant's selected quit date (56 to 63 days after enrollment)
Digital Therapeutic Alliance
Time Frame: 56 days after participant's selected quit date (56 to 63 days after enrollment)
The measure includes items from the Bonding and Confidence subscales from the Mobile Agnew Relationship Measure, a scale of digital therapeutic alliance. Two items from each of the Bonding and Confidence subscales were included. Each item was asked on a 4-point Likert scale from strongly disagree (1) to strongly agree (4). The subscale items were combined to give a total possible score of 16 and a range of 4 (low alliance) to 16 (high alliance). The measure is averaged by study group. Assessed in the 2-month follow-up.
56 days after participant's selected quit date (56 to 63 days after enrollment)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Justin White, PhD, University of California, San Francisco

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 9, 2022

Primary Completion (Actual)

May 31, 2022

Study Completion (Actual)

May 31, 2022

Study Registration Dates

First Submitted

January 26, 2022

First Submitted That Met QC Criteria

January 26, 2022

First Posted (Actual)

February 7, 2022

Study Record Updates

Last Update Posted (Estimated)

January 3, 2024

Last Update Submitted That Met QC Criteria

December 14, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 19-29335
  • NCI-2021-07004 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
  • P30AG012839 (U.S. NIH Grant/Contract)
  • R21CA238301 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cigarette Smoking-Related Carcinoma

Clinical Trials on Game Module

3
Subscribe